Nobilis Therapeutics
  • Home
  • Company
    • About
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • NBTX-001
    • Science behind NBTX-001
    • Clinical Development Program
    • Intellectual property
  • Inhalation Devices
    • Zephyrus™ Device
  • Contact Us
Select Page

Nobilis Therapeutics Signs Exclusive License Agreement with Harvard University for PTSD Treatment

by nobilistx | Mar 8, 2016 | Uncategorized | 0 comments

http://www.marketwired.com/press-release/nobilis-therapeutics-signs-exclusive-license-agreement-with-harvard-university-ptsd-2109502.htm

Nobilis Therapeutics Signs Exclusive License Agreement with Harvard University for PTSD Treatment

Submit a Comment Cancel reply

You must be logged in to post a comment.

News

  • Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Posttraumatic Stress Disorder December 6, 2019
  • Nobilis Therapeutics’ NBTX-001 Showed Beneficial Effects in an Animal Model of Autism December 3, 2019
  • US Patent is Granted for Nobilis Therapeutics Invention On the Use of Noble Gases to Treat Complications of Pregnancy November 26, 2019
  • Nobilis Therapeutics published an article “Combining Xenon Inhalation With Trauma Memory Reactivation to Reduce Symptoms of Posttraumatic Stress Disorder: Case Report, Justification of Approach, and Review of the Literature” in Primary Care Companion For CNS Disorders September 20, 2019
  • US Patent Granted for Nobilis Therapeutics Invention Covering the Use of Xenon in ALS August 27, 2019

Recent Posts

  • Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Posttraumatic Stress Disorder
  • Nobilis Therapeutics’ NBTX-001 Showed Beneficial Effects in an Animal Model of Autism
  • US Patent is Granted for Nobilis Therapeutics Invention On the Use of Noble Gases to Treat Complications of Pregnancy
  • Nobilis Therapeutics published an article “Combining Xenon Inhalation With Trauma Memory Reactivation to Reduce Symptoms of Posttraumatic Stress Disorder: Case Report, Justification of Approach, and Review of the Literature” in Primary Care Companion For CNS Disorders
  • US Patent Granted for Nobilis Therapeutics Invention Covering the Use of Xenon in ALS

Recent Comments

    Archives

    • December 2019
    • November 2019
    • September 2019
    • August 2019
    • July 2019
    • January 2019
    • December 2018
    • August 2018
    • June 2018
    • May 2018
    • February 2018
    • January 2018
    • December 2017
    • October 2017
    • June 2017
    • May 2017
    • April 2016
    • March 2016
    • January 2016

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Facebook
    • Twitter
    • Google
    • RSS

    Designed by GO | Powered by GOs